Ibrutinib increases the risk of hypertension and atrial fibrillation : systematic review and meta-analysis
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2019 |
| Outros Autores: | , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| Texto Completo: | http://hdl.handle.net/10451/37246 |
Resumo: | © 2019 Caldeira et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| id |
RCAP_e3a4728d758e6d1f8add7dd52e23fd30 |
|---|---|
| oai_identifier_str |
oai:repositorio.ul.pt:10451/37246 |
| network_acronym_str |
RCAP |
| network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| repository_id_str |
7160 |
| spelling |
Ibrutinib increases the risk of hypertension and atrial fibrillation : systematic review and meta-analysis© 2019 Caldeira et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.Introduction: Ibrutinib is an oral covalent inhibitor of Bruton's tyrosine kinase approved for the treatment of patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma and Waldenstrӧm’s macroglobulinemia. Ibrutinib has an increased risk of atrial fibrillation but the mechanism is unknown, and hypertension may play a role in the pathogenesis of this adverse drug reaction. Methods: We aimed to review the risk of hypertension and atrial fibrillation as adverse events associated with ibrutinib through a systematic review with meta-analysis of randomized controlled trials (RCTs) retrieved in December 2018 on MEDLINE, EMBASE, CENTRAL and ClinicalTrials.gov. The data were pooled using random-effects meta-analyses using the risk ratio (RR) with the 95% confidence interval (95%CI). The confidence on the pooled estimates was ascertained through the grading of recommendations assessment, development, and evaluation (GRADE) approach. Results: There were 8 eligible RCTs (2580 patients), all reporting safety data of interest. Ibrutinib was associated with a significant increase in the risk of hypertension with a RR of 2.82 (95%CI 1.52–5.23) with moderate quality evidence. Ibrutinib increased significantly the risk of atrial fibrillation with a RR of 4.69 (95%CI 2.17–7.64) with high quality evidence. Conclusions: Ibrutinib was associated with significantly increased risks of both hypertension and atrial fibrillation.UID/BIM/50005/2019, project funded by Fundação para a Ciência e a Tecnologia (FCT)/ Ministério da Ciência, Tecnologia e Ensino Superior (MCTES) through Fundos do Orçamento de Estado. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.PLoSRepositório da Universidade de LisboaCaldeira, DanielAlves, DanielaCosta, JoãoFerreira, Joaquim JPinto, Fausto J.2019-02-28T16:24:40Z20192019-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/37246engPLoS ONE 14(2): e02112281932-620310.1371/journal.pone.0211228info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-08T16:34:20Zoai:repositorio.ul.pt:10451/37246Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:51:20.798091Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
| dc.title.none.fl_str_mv |
Ibrutinib increases the risk of hypertension and atrial fibrillation : systematic review and meta-analysis |
| title |
Ibrutinib increases the risk of hypertension and atrial fibrillation : systematic review and meta-analysis |
| spellingShingle |
Ibrutinib increases the risk of hypertension and atrial fibrillation : systematic review and meta-analysis Caldeira, Daniel |
| title_short |
Ibrutinib increases the risk of hypertension and atrial fibrillation : systematic review and meta-analysis |
| title_full |
Ibrutinib increases the risk of hypertension and atrial fibrillation : systematic review and meta-analysis |
| title_fullStr |
Ibrutinib increases the risk of hypertension and atrial fibrillation : systematic review and meta-analysis |
| title_full_unstemmed |
Ibrutinib increases the risk of hypertension and atrial fibrillation : systematic review and meta-analysis |
| title_sort |
Ibrutinib increases the risk of hypertension and atrial fibrillation : systematic review and meta-analysis |
| author |
Caldeira, Daniel |
| author_facet |
Caldeira, Daniel Alves, Daniela Costa, João Ferreira, Joaquim J Pinto, Fausto J. |
| author_role |
author |
| author2 |
Alves, Daniela Costa, João Ferreira, Joaquim J Pinto, Fausto J. |
| author2_role |
author author author author |
| dc.contributor.none.fl_str_mv |
Repositório da Universidade de Lisboa |
| dc.contributor.author.fl_str_mv |
Caldeira, Daniel Alves, Daniela Costa, João Ferreira, Joaquim J Pinto, Fausto J. |
| description |
© 2019 Caldeira et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| publishDate |
2019 |
| dc.date.none.fl_str_mv |
2019-02-28T16:24:40Z 2019 2019-01-01T00:00:00Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10451/37246 |
| url |
http://hdl.handle.net/10451/37246 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
PLoS ONE 14(2): e0211228 1932-6203 10.1371/journal.pone.0211228 |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
PLoS |
| publisher.none.fl_str_mv |
PLoS |
| dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
| instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
| instacron_str |
RCAAP |
| institution |
RCAAP |
| reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
| repository.mail.fl_str_mv |
|
| _version_ |
1799134449127915520 |